Abgenix (NASDAQ:ABGX)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Abgenix Charts. Click Here for more Abgenix Charts.](/p.php?pid=staticchart&s=N%5EABGX&p=8&t=15)
Abgenix Appoints Donald R. Joseph as Senior Vice President,
General Counsel and Secretary
FREMONT, Calif., March 4 /PRNewswire-FirstCall/ -- Abgenix, Inc.
(NASDAQ:ABGX), a biopharmaceutical company focused on development of antibody
therapeutics, announced today the appointment of Donald R. Joseph as Senior
Vice President, General Counsel and Secretary.
"We are very pleased to have Don on board. He brings extensive legal and
commercial experience in the biotechnology and life sciences sectors," said
Bill Ringo, president and chief executive officer of Abgenix. "His experience
with pharmaceutical and biotech companies will provide Abgenix with legal
expertise that is essential as we prepare to bring our lead product,
panitumumab, to the market."
Mr. Joseph's appointment follows the departure of Susan L. Thorner, who
resigned earlier this year to pursue other opportunities.
Before joining Abgenix, Mr. Joseph was the co-founder of Alekta Group, LLC, a
specialty pharmaceutical consulting group and pharmaceutical development
company. Prior to Alekta he was the Executive Vice President, Commercial
Development of Amarin Corp., a Nasdaq-listed company based in London, and the
Executive Vice President, Legal and Commercial Development for Amarin
Pharmaceuticals, its U.S. subsidiary, for three years. He was responsible for
U.S. in-licensing and product acquisition transactions, commercial transition
for acquired products, U.S. legal affairs, human resources and administration.
From 1998 until 2001, Mr. Joseph worked at Elan Pharmaceuticals, the
pharmaceutical division of Elan Corporation, most recently as Senior Vice
President for commercial and legal affairs. Following Elan's acquisition of
Athena Neurosciences, Inc. in 1996, he served as Vice President and General
Counsel for Athena. From 1978 until 1993, Mr. Joseph practiced law with law
firms in Oklahoma, San Francisco and San Diego. Before joining Athena
Neurosciences in 1994, he was a partner in the San Francisco office of Baker &
McKenzie, a prominent international law firm.
Mr. Joseph received his law degree from the University of Texas Law School and
his undergraduate degree from the University of Oklahoma.
About Abgenix
Abgenix is a biopharmaceutical company focused on the discovery, development
and manufacturing of human therapeutic antibodies. The company's antibody
development platform includes a leading technology and state-of-the- art
manufacturing capabilities that enable the rapid generation, selection and
production of high affinity, fully human antibody product candidates to a
variety of disease targets. Abgenix leverages its leadership position in human
antibody technology to build a diversified product portfolio through its own
development efforts and the establishment of collaborations with multiple
pharmaceutical and biotechnology companies. For more information on Abgenix,
visit the company's website at http://www.abgenix.com/.
Statements made in this press release about Abgenix's technologies, product
development activities, collaborative arrangements and process science and
manufacturing capabilities, other than statements of historical fact, and about
its projected financial results and the achievement of milestone or similar
payments, are forward-looking statements and are subject to a number of
uncertainties that could cause actual results to differ materially from the
statements made, including risks associated with the success of clinical
trials, the progress of research and product development programs, product
manufacturing, regulatory approval processes, competitive products and
services, future capital requirements and the extent and breadth of Abgenix's
patent portfolio. Please see Abgenix's public filings with the Securities and
Exchange Commission for information about risks that may affect Abgenix.
DATASOURCE: Abgenix, Inc.
CONTACT: Ami Knoefler, Senior Director, Corporate Communications and
Investor Relations of Abgenix, Inc., +1-510-284-6350 or +1-510-284-6605
Web site: http://www.abgenix.com/